|
000
| 01548cam 2200301za 4500 |
|---|
| 001 | 9.847576 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153455 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171122s2018 onc o f000 0 eng d |
|---|
| 020 | |a9780660239583|z9780660239590 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-174/2017E-PDF |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aPeptides against cancer (L-11627/11964) |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
|---|
| 300 | |a[1] p. |
|---|
| 500 | |aIssued also in French under title: Peptides contre le cancer (L-11627/11964). |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"December 2017." |
|---|
| 520 | |a“NRC has developed peptides with novel anti-angiogenic properties that are effective against many different stimulators of angiogenesis. The NRC peptides exhibit direct anti-tumorogenic properties against different types of tumors and have been validated in vivo. The antiangiogenic activity against multiple stimulators, combined with the direct inhibition of tumour growth, position these peptides as promising treatments against malignant tumours”--Highlights. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aNeovascularization inhibitors |
|---|
| 693 | 4|aPeptides |
|---|
| 775 | 08|tPeptides contre le cancer (L-11627/11964) |w(CaOODSP)9.847578 |
|---|
| 776 | 0#|tHHT peptides against cancer |w(CaOODSP)9.847577 |
|---|
| 856 | 40|qPDF|s152 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-174-2017-eng.pdf |
|---|